PRESS RELEASE: EORTC and CDDF announce new collaboration

CDDF provides a neutral platform to stimulate interactions between all stakeholders involved in cancer drug development. The aim of the organization is to accelerate the delivery of effective oncology agents to patients by encouraging multi-stakeholder discussions.

The collaboration will foster dialogue on common issues in clinical cancer research especially with other stakeholders. Both organisations intend to organise joint workshops and offer support and endorsement in each other’s events.

“Through the partnership with EORTC, one of the most important academic clinical research organizations worldwide, we believe we are offering unique value to stimulate advancement in oncology treatment and delivery” said Professor Jaap Verweij, CDDF Managing Director. “We believe collaboration is the key to improving outcomes for cancer patients and we look forward to a strong alliance with EORTC that will help identify and overcome challenges in the development and delivery of cancer drugs and deliver swift benefits to cancer patients.”

“This is an important partnership for EORTC,” said Dr Denis Lacombe, EORTC Director General. “CDDF has been instrumental in discussions with regulators and other stakeholders and with our combined efforts, we can bring challenging issues to the wider oncology community producing effective outcomes.”

About EORTC

EORTC, an academic clinical research organization, bringing together European clinical investigators from all disciplines across all tumour types to conduct research that improves quality of life and survival of cancer patients. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life. EORTC network comprises more than 5300 professionals in over 1000 hospitals and institutes in more than 30 countries supported by 230 staff in its Headquarters in Brussels.

About CDDF

The Cancer Drug Development Forum (CDDF) is a leading non-competitive drug development platform in Europe whose sole objective is to stimulate advancement in cancer drug development and access.

CDDF integrative approach aims to bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to accelerate effective drug development in oncology treatment and shorten time to market, and time to patient access.

For more information on Cancer Drug Development Forum, please visit www.cddf.org